Marshall Wace
FBRX

Marshall Wace’s Forte Biosciences FBRX Stock Holding History

Marshall Wace’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-150,307
Closed -$3.89M – 3341
2026
Q1 		$3.89M Buy
150,307
+114,010
+314% +$3.28M ﹤0.01% 1423
2025
Q4 		$990K Buy
36,297
+17,132
+89% +$300K ﹤0.01% 1939
2025
Q3 		$287K Buy
+19,165
New +$221K ﹤0.01% 2446
2021
Q3 		– Sell
-1,063
Closed -$893K – 3138
2021
Q2 		$893K Buy
1,063
+812
+324% +$732K ﹤0.01% 1875
2021
Q1 		$215K Buy
+251
New +$206K ﹤0.01% 2237
2019
Q1 		– Sell
-107
Closed -$328K – 1821
2018
Q4 		$328K Buy
+107
New +$461K ﹤0.01% 1207

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Marshall Wace's FBRX Position: Q2 2026 in Review

Marshall Wace sold out of Forte Biosciences (FBRX) in Q2 2026, closing a stake of 150,307 shares — an estimated $3.89M sold.

Marshall Wace first reported a position in FBRX in Q4 2018 and held it in 6 quarters. The position peaked at $3.89M in Q1 2026. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Marshall Wace reported no remaining Forte Biosciences position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 150,307 Forte Biosciences shares in Q2 2026, an estimated $3.89M.
  • Marshall Wace first reported a position in Forte Biosciences in Q4 2018 and held it in 6 quarters.
  • Marshall Wace's Forte Biosciences position peaked at $3.89M in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.